Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease.
about
Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trialNonalcoholic fatty liver disease: an emerging threat to obese and diabetic individualsDrugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitisOmega-3 polyunsaturated fatty acids for non-alcoholic fatty liver diseaseWeight reduction for non-alcoholic fatty liver diseaseWeight reduction for non-alcoholic fatty liver diseaseProbiotics for non-alcoholic fatty liver disease and/or steatohepatitisAntioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitisDrugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitisNonalcoholic fatty liver diseaseNon-alcoholic fatty liver disease and mortality among US adults: prospective cohort studyMetabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential linkMeasurement of the total antioxidant response using a novel automated method in subjects with nonalcoholic steatohepatitis.The Natural Course of Non-Alcoholic Fatty Liver DiseaseSurveillance for Hepatocellular Carcinoma in Patients with NASHContribution of the toxic advanced glycation end-products-receptor axis in nonalcoholic steatohepatitis-related hepatocellular carcinomaPathogenesis of hepatocarcinogenesis in non-cirrhotic nonalcoholic fatty liver disease: Potential mechanistic pathwaysAdvances in hepatocellular carcinoma: Nonalcoholic steatohepatitis-related hepatocellular carcinomaFructose as a key player in the development of fatty liver diseasePathophysiology of insulin resistance and steatosis in patients with chronic viral hepatitisPrevalence and determinants of biochemical dysfunction of the liver in Atayal Aboriginal community of Taiwan: Is betel nut chewing a risk factor?Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesisMetabolic and cardiovascular complications in the liver transplant recipientNon-alcoholic fatty liver disease: need for a balanced nutritional sourcePrevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994Obesity and non-alcoholic fatty liver disease: Disparate associations among Asian populationsThe potential interplay of adipokines with toll-like receptors in the development of hepatocellular carcinomaChanges in hepatic gene expression upon oral administration of taurine-conjugated ursodeoxycholic acid in ob/ob miceInflammasome-mediated dysbiosis regulates progression of NAFLD and obesityThe global epidemiology of hepatocellular carcinoma: present and futureNAFLD and liver transplantation: Current burden and expected challenges.A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis.Is NASH underdiagnosed among African Americans?Subacute liver failure in obese women.Indications of Liver Biopsy in the Era of Noninvasive Assessment of Liver FibrosisNon-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology.The effects of diet composition on body fat and hepatic steatosis in an animal (Peromyscus californicus) model of the metabolic syndrome.Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetesSurvival of patients with alcoholic and cryptogenic cirrhosis without liver transplantation: a single center retrospective study.
P2860
Q22242637-8E3B5039-03D7-49C9-8570-6BE6CA41827DQ22299426-975B2377-E100-4ECC-B8ED-5C0655F1923BQ24197984-3693346B-BAB5-4AA7-BF11-4A3F24289FB7Q24202688-51C7563B-4B6C-473E-94CC-EFA10B3560ECQ24235200-56CF737D-FBCA-4473-B1DE-ABDC7D60B29BQ24236500-6AB066C1-4BFC-44F8-A603-76EBEC371483Q24243033-B6EB4FED-D5A5-4FCB-9957-2A4ECFDB9F75Q24243125-2ACD119D-D81A-4858-81A5-382EED6ED3E6Q24246447-483EB645-57DF-4889-8C13-BB93B95C65F4Q24555779-90564819-E926-4A6F-B93D-F78944C7D654Q24596256-5E7BE884-58A0-4DDE-92BF-1D01DF473937Q24631619-69485BE8-C4F1-4191-8448-CB62668F0C89Q24815160-DD91F376-CA42-4D8E-AC4B-0DED8942A466Q26746947-97799C18-5824-484E-901E-65E72FE7BFB1Q26747428-185716AF-58CB-40E2-896B-B1BBF8F40D35Q26781477-596A75EC-246E-4391-9E62-4C348702A269Q26783372-72997270-FF4C-4C81-B76A-B1A51274A1C3Q26795529-6BE3C326-BFFE-46D2-B50E-E11B1DFC7CBAQ27014596-6305E293-01D9-43E9-BA73-206B479F900BQ27022707-394BC70F-4F1C-484A-BDC6-FB0128E52892Q27486400-3601BEA8-0CAD-49E5-B5B8-C75AEAC5316BQ27489394-74D02741-C412-424C-AE25-AFA58A9F5597Q28082243-90A9AEF1-8531-4366-B81E-7AAB572C48A4Q28248994-EDF5D3EF-80EA-470B-8BFB-47D645187F14Q28384968-45E95768-FF13-4733-95B1-80256870326BQ28386598-7AF38DA0-30E4-4CA6-95CA-185667B6AA30Q28392224-5920814F-BCBE-44A2-B29A-62A1344406DFQ28476015-BD3EC8F3-674E-4955-8434-71E5E6A65976Q28512778-0BC6B36B-7408-476C-BB36-C299891A8C87Q28654353-58602D7B-EF68-49E5-BEF4-8C4D5A564ADCQ30248646-A224B5AF-C1AB-4D4F-922A-2DE4015B91A5Q30306955-B8808CBC-20A1-4EEE-A47C-E8AD03BAE8AFQ30309598-817518D8-3A37-4043-B4DF-F98044DBB84AQ30309852-E161E960-3A13-43A6-A377-456B76601C8DQ30368738-12B7F759-D13C-4FE0-9686-37C03C033FA5Q30389752-925D06EE-3FE9-45DC-B61F-BFF41EA705EBQ30431218-9335C1BC-29FB-438E-A3E5-737B3A81428EQ30479629-27ECD668-37B8-4950-A80E-6C03C75B57EDQ30496725-ABDC77D4-7785-4CF4-A74E-C146C0221392Q31107490-8E2E1E7B-D8BB-47D7-A7B3-12A09727C8B0
P2860
Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease.
description
1999 nî lūn-bûn
@nan
1999 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մարտին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease.
@ast
Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease.
@en
type
label
Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease.
@ast
Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease.
@en
prefLabel
Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease.
@ast
Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease.
@en
P2093
P356
P1433
P1476
Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease.
@en
P2093
Caldwell SH
Driscoll CJ
Hespenheide EE
Iezzoni JC
Oelsner DH
P304
P356
10.1002/HEP.510290347
P407
P577
1999-03-01T00:00:00Z